(12) United States Patent (10) Patent No.: US 7,749,544 B2 Asiedu Et Al
Total Page:16
File Type:pdf, Size:1020Kb
US0077.49544B2 (12) United States Patent (10) Patent No.: US 7,749,544 B2 Asiedu et al. (45) Date of Patent: Jul. 6, 2010 (54) COMPOSITION FORTREATING AIDS AND (56) References Cited ASSOCATED CONDITIONS OTHER PUBLICATIONS (76) Inventors: William Asiedu, H/N B 183/19 Bintu Area, PMB Ministries, Accra (GH): Calderon et al. (Phytotherapy Research (1997), vol. 11, pp. 606 s s s 608).* Rede hist No. 1ntu Ojewole (International Journal of Crude Drug Research (1984), vol. s s ; : 22, No. 3, pp. 121-143).* Manny Ennin, H/N B 183/19 Bintu Ginsberg and Spigelman (Nature Medicine (2007), vol. 13, No.3, pp. Area, PMB Ministries, Accra (GH): 290–294).* Michael Nsiah Doudu, H/N B 183/19 Engler and Prantl, Die Naturlichen. Pflanzenfamilien, 1897, p. 349. Bintu Area, PMB Ministries, Accra Breteler, F.J. “Novitates Gabonenses 47. Another new Dichapetalum (GH); Charles Antwi Boateng, H/N B (Dichapetalaceae) from Gabon' Adansonia, 2003; 25(2):223-227. 183/19 Bintu Area, PMB Ministries, Fedkam Boyometal. "Aromatic plants of tropical central Africa. Part Accra (GH); Kwasi Appiah-Kubi, H/N XLIII: volatile components from Uvariastrum pierreanum Engl. B 183/19 B int Area. PMB MinistriCS (Engl. & Diels) growing in Cameroon' Flavour and Fragrance Jour Accra (GH); Seth Opoku Ware, H/N B nal, 2003; 18:269-298. 183/19 Bintu Area, PMB Ministries, * cited by examiner Accra (GH); Debrah Boateng, H/N B 183/19 Bintu Area, PMB Ministries, Primary Examiner Susan C Hoffman Accra (GH); Kofi Ampim, 2 Kakramadu (74) Attorney, Agent, or Firm—Frommer Lawrence & Haug Ling, P.O. Box CT 245, Cantonments, LLP; Marilyn Matthes Brogan: Heather J. DiPietrantonio Owusu,PMB Ministries, H/N B 183/19 Accra Bintu(GH); Area, William PMB (57) ABSTRACT Ministries, Accra (GH); Akwete Lex Adjei, 15 Tillman Ct. Bridgewater, NJ An Aids and associated conditions related to Aids treating (US)US) 08807 COmoS1t1OnSpositi 1Sis disclosed.d1SCIOSed. ThThe COmoS1t1OnSpositi COmr1Se:pri a (*)*) Notice: SubiectN tO E. disclaite the tfWi. f thi followingmedicament plant selected families: from Apocynaceae an extract of (Pleioscarpa at least one Bicarof the p ls: e O G adjusted under pellata); Annonaceae (Cleistopholis Patens); Dichapetal M YW- (b) by yS. aceae (Dichapetehan Madagasca Riense); Annoceae (Uvaristrum Pierreanum); Cynocynaceae (Strophantus Gra (21) Appl. No.: 10/902,993 tus); Asclepiadaceae (Gongronema Latifolium); Combreta (22) Filed: Ul. 30, 2004 ceae (Combretum Racemosum); Apocynaceae (Alostonia 9 Boonei); Amaranthaceae (Alternanthera Pungens); Aroceae (65) Prior Publication Data (Anchomanes Differmis); Cyperaceae (Seleria Voivinil); Anacardiaceae (Lannea Acida); Bignoniaceae (Kigelia Afri US 2005/O181077 A1 Aug. 18, 2005 cana); Bombacaceae (Ceiba Pentanota); Anarcardiaceae O O (Antrocaryon Micraster); Bombacaceae (Bombax Bounopo Related U.S. Application Data zense): Anarcardiaceae (Spondias Mombin); Caricaceae (63) Continuation of application No. 10/241,973, filed on (Carica Papaya); a glyceryl ester of any of the foregoing Sep. 12, 2002, now abandoned. extracts; a saponin of any of the foregoing extracts; an alka loid of any of the foregoing extracts; a protein of any of the (51) Int. Cl. foregoing extracts; a fat of any of the foregoing extracts; a A6 IK 36/00 (2006.01) Sugar of any of the foregoing extracts; and any mixture of any (52) U.S. Cl. ...................................................... 424/725 of the foregoing. (58) Field of Classification Search ....................... None See application file for complete search history. 3 Claims, No Drawings US 7,749,544 B2 1. 2 COMPOSITION FORTREATING AIDS AND persons are of value. These estimates can be obtained through ASSOCATED CONDITIONS epidemiologic studies or special Surveys in specific popula tions. This application is a continuation of U.S. application Ser. Issues related to the case definition of AIDS were discussed No. 10/241,973, filed Sep. 12, 2002, now abandoned. 5 by the Conference of State and Territorial Epidemiologists (CSTE) at its annual meeting in Madison, Wis., Jun. 2-5. BACKGROUND OF THE INVENTION 1985. The CSTE approved the following resolutions: 1. that the case definition of AIDS used for national report 1. Field of the Invention ing continue to include only the more severe manifesta This invention relates to a composition for treating AIDS 10 tions of HTLV-III/LAV infection; and and related conditions, and more particular, to a composition 2. that the Center For Disease Control (CDC) develop more comprising at least one extract of a selected plant. inclusive definitions and classifications of HTLV-III/ 2. Description of the Prior Art LAV infection for diagnosis, treatment, and prevention, Patients with illnesses that, in retrospect, were manifesta as well as for epidemiologic studies and special Surveys; tions of acquired immunodeficiency syndrome (AIDS) were 15 and first described in the summer of 1981 CDC Pneumocystis 3. that the following refinements be adopted in the case pneumonia Los Angeles. MMWR 1981, 30:250-2; CDC - definition of AIDS used for national reporting: Kaposi's sarcoma and Pneumocystis pneumonia among a. In the absence of the opportunistic diseases required homosexual men—New York City and California. MMWR by the current case definition, any of the following 1981, 30:305-8. A case definition of AIDS for national diseases will be considered indicative of AIDS if the reporting was first published in the MMWR in September patient has a positive serologic or Virologic test for 1982 CDC Hepatitis B virus vaccine safety: report of an HTLV-IIIALAV: inter-agency group MMWR 1982, 31:465-67: CDC Up 1. disseminated histoplasmosis (not confined to lungs or date on acquired immune deficiency syndrome (AIDS)— lymph nodes), diagnosed by culture, histology, or anti United States. MMWR 1982, 31:507-14. Since then the 25 gen detection; definition has undergone minor revisions in the list of dis 2. isosporiasis, causing chronic diarrhea (over 1 month), eases used as indicators of underlying cellular immunodefi diagnosed by histology or stool microscopy; ciency Jaffe HW. Bregman DJ, Selik RM. Acquired immune 3. bronchial or pulmonary candidiasis, diagnosed by deficiency syndrome in the United States: the first 1,000 microscopy or by presence of characteristic white cases. J Infect Dis 1983, 148:339-45; Jaffe H.W. Selik RM. 30 plaques grossly on the bronchial mucosa (not by culture Acquired immune deficiency syndrome. is disseminated alone); aspergillosis predictive of underlying cellular immune defi 4. non-Hodgkins' lymphoma of high-grade pathologic ciency?, (Reply to letter), J Infect Dis 1984, 149:829; Selik R type (diffuse, undifferentiated) and of B-cell unknown M. Haverkos H W. Curran J. W. Acquired immune deficiency immunologic phenotype, diagnosed by biopsy: syndrome (AIDS) trends in the United States, 1978-1982. Am 35 5. histologically confirmed Kaposi's sarcoma in patients J Med 1984, 76:493-500; CDC, Update: acquired immuno who are 60 years old or older when diagnosed. deficiency syndrome (AIDS) United States. MMWR 1984, b. In the absence of the opportunistic diseases required 32:688-91 by the current case definition, a histologically con Since the 1982 definition was published, human T-cell firmed diagnosis of chronic lymphoid interstitial lymphotropic virus type III/lymphadenopathy-associated 40 pneumonitis in a child (under 13 years of age) will be virus (HTLV-III/LAV) has been recognized as the cause of considered indicative of AIDS unless test(s) for AIDS. The clinical manifestations of (HTLV-III/LAV) infec HTLV-III/LAV are negative. tion may be directly attributable to infection with this virus or c. Patients who have a lymphoreticular malignancy the result of secondary conditions occurring as a consequence diagnosed more than 3 months after the diagnosis of of immune dysfunction caused by the underlying infection 45 an opportunistic disease used as a marker for AIDS with (HTLV-III/LAV). The range of manifestations may will no longer be excluded as AIDS cases. include none, nonspecific signs and symptoms of illness, d. To increase the specificity of the case definition, autoimmune and neurologic disorders, a variety of opportu patients will be excluded as AIDS cases if they have a nistic infections, and several types of malignacy. AIDS was negative result on testing for serum antibody to defined for national reporting before its etiology was known 50 HTLV-III/LAV, have no other type of HTLV-III/LAV and has encompassed only certain secondary conditions that test with a positive result, and do not have a low reliably reflected the presence of a sever immune dysfunc number of T-helper lymphocytes or a low ratio of tion. Current laboratory tests to detect (HTLV-III/LAV) anti T-helper to T-Suppressor lymphocytes. In the absence body make it possible to include additional serious conditions of test results, patients satisfying all other criteria in in the syndrome, as well as to further improve the specificity 55 the definition will continue to be included. CDC will of the definition used for reporting cases. immediately adopt the above amendments to the case The current case definition of AIDS has provided useful definition of AIDS for national reporting. data on disease trends, because it is precise, consistently This revision, in the case definition will result in the reclas interpreted, and highly specific. Other manifestations of sification of less than 1% of cases previously reported to HTLV-III/LAV infections than those currently proposed to be 60 CDC. The number of additional new cases reportable as a reported are less specific and less likely to be consistently result of the revision is expected to be small. Cases included reported nationally. Milder disease associated with HTLV-III/ under the revised definition will be distinguishable from cases LAV infections and asymptomatic infections may be report included under the old definition so as to provide a consistent able in some states and cities but will not be nationally report basis for interpretation of trends.